Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged ≥60 years: an open-label, randomised trial.
Identifieur interne : 000210 ( Main/Exploration ); précédent : 000209; suivant : 000211Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged ≥60 years: an open-label, randomised trial.
Auteurs : Ulrich Zimmermann [Allemagne] ; Gaëtan Gavazzi ; Patrick Richard ; Cécile Eymin ; Benoît Soubeyrand ; Martine BaudinSource :
- Vaccine [ 1873-2518 ] ; 2013.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen (MeSH), Allemagne (MeSH), Anticorps antibactériens (sang), Anticorps antiviraux (sang), Effets secondaires indésirables des médicaments (anatomopathologie), Effets secondaires indésirables des médicaments (épidémiologie), Femelle (MeSH), France (MeSH), Humains (MeSH), Mâle (MeSH), Rappel de vaccin (effets indésirables), Sujet âgé (MeSH), Vaccin antipoliomyélitique inactivé (administration et posologie), Vaccin antipoliomyélitique inactivé (effets indésirables), Vaccin antipoliomyélitique inactivé (immunologie), Vaccin diphtérie-tétanos-coqueluche (administration et posologie), Vaccin diphtérie-tétanos-coqueluche (effets indésirables), Vaccin diphtérie-tétanos-coqueluche (immunologie), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (effets indésirables), Vaccins antigrippaux (immunologie), Vaccins combinés (administration et posologie), Vaccins combinés (effets indésirables), Vaccins combinés (immunologie), Vaccins inactivés (administration et posologie), Vaccins inactivés (effets indésirables), Vaccins inactivés (immunologie).
- MESH :
- administration et posologie : Vaccin antipoliomyélitique inactivé, Vaccin diphtérie-tétanos-coqueluche, Vaccins antigrippaux, Vaccins combinés, Vaccins inactivés.
- anatomopathologie : Effets secondaires indésirables des médicaments.
- effets indésirables : Rappel de vaccin, Vaccin antipoliomyélitique inactivé, Vaccin diphtérie-tétanos-coqueluche, Vaccins antigrippaux, Vaccins combinés, Vaccins inactivés.
- immunologie : Vaccin antipoliomyélitique inactivé, Vaccin diphtérie-tétanos-coqueluche, Vaccins antigrippaux, Vaccins combinés, Vaccins inactivés.
- sang : Anticorps antibactériens, Anticorps antiviraux.
- épidémiologie : Effets secondaires indésirables des médicaments.
- Adulte d'âge moyen, Allemagne, Femelle, France, Humains, Mâle, Sujet âgé.
- Wicri :
English descriptors
- KwdEn :
- Aged (MeSH), Antibodies, Bacterial (blood), Antibodies, Viral (blood), Diphtheria-Tetanus-Pertussis Vaccine (administration & dosage), Diphtheria-Tetanus-Pertussis Vaccine (adverse effects), Diphtheria-Tetanus-Pertussis Vaccine (immunology), Drug-Related Side Effects and Adverse Reactions (epidemiology), Drug-Related Side Effects and Adverse Reactions (pathology), Female (MeSH), France (MeSH), Germany (MeSH), Humans (MeSH), Immunization, Secondary (adverse effects), Influenza Vaccines (administration & dosage), Influenza Vaccines (adverse effects), Influenza Vaccines (immunology), Male (MeSH), Middle Aged (MeSH), Poliovirus Vaccine, Inactivated (administration & dosage), Poliovirus Vaccine, Inactivated (adverse effects), Poliovirus Vaccine, Inactivated (immunology), Vaccines, Combined (administration & dosage), Vaccines, Combined (adverse effects), Vaccines, Combined (immunology), Vaccines, Inactivated (administration & dosage), Vaccines, Inactivated (adverse effects), Vaccines, Inactivated (immunology).
- MESH :
- chemical , administration & dosage : Diphtheria-Tetanus-Pertussis Vaccine, Influenza Vaccines, Poliovirus Vaccine, Inactivated, Vaccines, Combined, Vaccines, Inactivated.
- chemical , adverse effects : Diphtheria-Tetanus-Pertussis Vaccine, Influenza Vaccines, Poliovirus Vaccine, Inactivated, Vaccines, Combined, Vaccines, Inactivated.
- chemical , blood : Antibodies, Bacterial, Antibodies, Viral.
- chemical , immunology : Diphtheria-Tetanus-Pertussis Vaccine, Influenza Vaccines, Poliovirus Vaccine, Inactivated, Vaccines, Combined, Vaccines, Inactivated.
- geographic : France, Germany.
- adverse effects : Immunization, Secondary.
- epidemiology : Drug-Related Side Effects and Adverse Reactions.
- pathology : Drug-Related Side Effects and Adverse Reactions.
- Aged, Female, Humans, Male, Middle Aged.
Abstract
BACKGROUND
Annual influenza vaccination provides an opportunity to administer a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV) to the elderly. This study evaluated immune responses to and safety of the two vaccines administered concomitantly or sequentially to elderly individuals in France and Germany.
METHODS
Individuals aged ≥60 years who had received a diphtheria/tetanus booster within 5-15 years were randomised (1:1) to receive either Tdap-IPV and an inactivated influenza vaccine concomitantly (Group 1) or inactivated influenza vaccine then Tdap-IPV 28-35 days later (Group 2). Antibody titres were measured before and 28-35 days after each vaccination.
RESULTS
The mean age of randomised individuals (n=954) was 68.8 years. Post-vaccination seroprotection rates (≥0.1 IU/mL for diphtheria/tetanus and ≥8 1/dilution for polio) for Group 1 were non-inferior to Group 2 for diphtheria (85.4% vs. 87.5%), tetanus (both 100%), polio type 1 (99.8% vs. 100%), polio type 2 (both 100%) and polio type 3 (99.3% vs. 99.8%). Similarly, percentages of individuals with pertussis antibodies ≥5 EU/mL for Group 1 were non-inferior to Group 2: pertussis toxin (94.3% vs. 98.1%), filamentous haemagglutinin (99.8% vs. 100%), pertactin (97.3% vs. 96.0%), fimbriae 2 and 3 (91.7% vs. 89.5%). Post-vaccination geometric mean titres of anti-influenza haemagglutinin antibodies for Group 1 were non-inferior to Group 2. Adverse events following administration of Tdap-IPV were similar in both study groups, with no vaccine-related serious adverse events.
CONCLUSION
Tdap-IPV and inactivated influenza vaccine can be administered concomitantly in the elderly without impairing tolerability or the immune response to either vaccine.
DOI: 10.1016/j.vaccine.2012.12.081
PubMed: 23313654
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged ≥60 years: an open-label, randomised trial.</title><author><name sortKey="Zimmermann, Ulrich" sort="Zimmermann, Ulrich" uniqKey="Zimmermann U" first="Ulrich" last="Zimmermann">Ulrich Zimmermann</name><affiliation wicri:level="1"><nlm:affiliation>Internistische Gemeinschaftspraxis, Sülmerstraße 32, D74072, Heilbronn, Germany. Dr.UlrichZimmermann@web.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Internistische Gemeinschaftspraxis, Sülmerstraße 32, D74072, Heilbronn</wicri:regionArea><wicri:noRegion>74072, Heilbronn</wicri:noRegion><wicri:noRegion>74072, Heilbronn</wicri:noRegion><wicri:noRegion>Heilbronn</wicri:noRegion></affiliation></author><author><name sortKey="Gavazzi, Gaetan" sort="Gavazzi, Gaetan" uniqKey="Gavazzi G" first="Gaëtan" last="Gavazzi">Gaëtan Gavazzi</name></author><author><name sortKey="Richard, Patrick" sort="Richard, Patrick" uniqKey="Richard P" first="Patrick" last="Richard">Patrick Richard</name></author><author><name sortKey="Eymin, Cecile" sort="Eymin, Cecile" uniqKey="Eymin C" first="Cécile" last="Eymin">Cécile Eymin</name></author><author><name sortKey="Soubeyrand, Benoit" sort="Soubeyrand, Benoit" uniqKey="Soubeyrand B" first="Benoît" last="Soubeyrand">Benoît Soubeyrand</name></author><author><name sortKey="Baudin, Martine" sort="Baudin, Martine" uniqKey="Baudin M" first="Martine" last="Baudin">Martine Baudin</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23313654</idno><idno type="pmid">23313654</idno><idno type="doi">10.1016/j.vaccine.2012.12.081</idno><idno type="wicri:Area/Main/Corpus">000208</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000208</idno><idno type="wicri:Area/Main/Curation">000208</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000208</idno><idno type="wicri:Area/Main/Exploration">000208</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged ≥60 years: an open-label, randomised trial.</title><author><name sortKey="Zimmermann, Ulrich" sort="Zimmermann, Ulrich" uniqKey="Zimmermann U" first="Ulrich" last="Zimmermann">Ulrich Zimmermann</name><affiliation wicri:level="1"><nlm:affiliation>Internistische Gemeinschaftspraxis, Sülmerstraße 32, D74072, Heilbronn, Germany. Dr.UlrichZimmermann@web.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Internistische Gemeinschaftspraxis, Sülmerstraße 32, D74072, Heilbronn</wicri:regionArea><wicri:noRegion>74072, Heilbronn</wicri:noRegion><wicri:noRegion>74072, Heilbronn</wicri:noRegion><wicri:noRegion>Heilbronn</wicri:noRegion></affiliation></author><author><name sortKey="Gavazzi, Gaetan" sort="Gavazzi, Gaetan" uniqKey="Gavazzi G" first="Gaëtan" last="Gavazzi">Gaëtan Gavazzi</name></author><author><name sortKey="Richard, Patrick" sort="Richard, Patrick" uniqKey="Richard P" first="Patrick" last="Richard">Patrick Richard</name></author><author><name sortKey="Eymin, Cecile" sort="Eymin, Cecile" uniqKey="Eymin C" first="Cécile" last="Eymin">Cécile Eymin</name></author><author><name sortKey="Soubeyrand, Benoit" sort="Soubeyrand, Benoit" uniqKey="Soubeyrand B" first="Benoît" last="Soubeyrand">Benoît Soubeyrand</name></author><author><name sortKey="Baudin, Martine" sort="Baudin, Martine" uniqKey="Baudin M" first="Martine" last="Baudin">Martine Baudin</name></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term><term>Antibodies, Bacterial (blood)</term><term>Antibodies, Viral (blood)</term><term>Diphtheria-Tetanus-Pertussis Vaccine (administration & dosage)</term><term>Diphtheria-Tetanus-Pertussis Vaccine (adverse effects)</term><term>Diphtheria-Tetanus-Pertussis Vaccine (immunology)</term><term>Drug-Related Side Effects and Adverse Reactions (epidemiology)</term><term>Drug-Related Side Effects and Adverse Reactions (pathology)</term><term>Female (MeSH)</term><term>France (MeSH)</term><term>Germany (MeSH)</term><term>Humans (MeSH)</term><term>Immunization, Secondary (adverse effects)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (adverse effects)</term><term>Influenza Vaccines (immunology)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Poliovirus Vaccine, Inactivated (administration & dosage)</term><term>Poliovirus Vaccine, Inactivated (adverse effects)</term><term>Poliovirus Vaccine, Inactivated (immunology)</term><term>Vaccines, Combined (administration & dosage)</term><term>Vaccines, Combined (adverse effects)</term><term>Vaccines, Combined (immunology)</term><term>Vaccines, Inactivated (administration & dosage)</term><term>Vaccines, Inactivated (adverse effects)</term><term>Vaccines, Inactivated (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen (MeSH)</term><term>Allemagne (MeSH)</term><term>Anticorps antibactériens (sang)</term><term>Anticorps antiviraux (sang)</term><term>Effets secondaires indésirables des médicaments (anatomopathologie)</term><term>Effets secondaires indésirables des médicaments (épidémiologie)</term><term>Femelle (MeSH)</term><term>France (MeSH)</term><term>Humains (MeSH)</term><term>Mâle (MeSH)</term><term>Rappel de vaccin (effets indésirables)</term><term>Sujet âgé (MeSH)</term><term>Vaccin antipoliomyélitique inactivé (administration et posologie)</term><term>Vaccin antipoliomyélitique inactivé (effets indésirables)</term><term>Vaccin antipoliomyélitique inactivé (immunologie)</term><term>Vaccin diphtérie-tétanos-coqueluche (administration et posologie)</term><term>Vaccin diphtérie-tétanos-coqueluche (effets indésirables)</term><term>Vaccin diphtérie-tétanos-coqueluche (immunologie)</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (effets indésirables)</term><term>Vaccins antigrippaux (immunologie)</term><term>Vaccins combinés (administration et posologie)</term><term>Vaccins combinés (effets indésirables)</term><term>Vaccins combinés (immunologie)</term><term>Vaccins inactivés (administration et posologie)</term><term>Vaccins inactivés (effets indésirables)</term><term>Vaccins inactivés (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Diphtheria-Tetanus-Pertussis Vaccine</term><term>Influenza Vaccines</term><term>Poliovirus Vaccine, Inactivated</term><term>Vaccines, Combined</term><term>Vaccines, Inactivated</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Diphtheria-Tetanus-Pertussis Vaccine</term><term>Influenza Vaccines</term><term>Poliovirus Vaccine, Inactivated</term><term>Vaccines, Combined</term><term>Vaccines, Inactivated</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Bacterial</term><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Diphtheria-Tetanus-Pertussis Vaccine</term><term>Influenza Vaccines</term><term>Poliovirus Vaccine, Inactivated</term><term>Vaccines, Combined</term><term>Vaccines, Inactivated</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>France</term><term>Germany</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccin antipoliomyélitique inactivé</term><term>Vaccin diphtérie-tétanos-coqueluche</term><term>Vaccins antigrippaux</term><term>Vaccins combinés</term><term>Vaccins inactivés</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Immunization, Secondary</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Effets secondaires indésirables des médicaments</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Rappel de vaccin</term><term>Vaccin antipoliomyélitique inactivé</term><term>Vaccin diphtérie-tétanos-coqueluche</term><term>Vaccins antigrippaux</term><term>Vaccins combinés</term><term>Vaccins inactivés</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccin antipoliomyélitique inactivé</term><term>Vaccin diphtérie-tétanos-coqueluche</term><term>Vaccins antigrippaux</term><term>Vaccins combinés</term><term>Vaccins inactivés</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antibactériens</term><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Effets secondaires indésirables des médicaments</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Allemagne</term><term>Femelle</term><term>France</term><term>Humains</term><term>Mâle</term><term>Sujet âgé</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>France</term><term>Allemagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Annual influenza vaccination provides an opportunity to administer a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV) to the elderly. This study evaluated immune responses to and safety of the two vaccines administered concomitantly or sequentially to elderly individuals in France and Germany.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Individuals aged ≥60 years who had received a diphtheria/tetanus booster within 5-15 years were randomised (1:1) to receive either Tdap-IPV and an inactivated influenza vaccine concomitantly (Group 1) or inactivated influenza vaccine then Tdap-IPV 28-35 days later (Group 2). Antibody titres were measured before and 28-35 days after each vaccination.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>The mean age of randomised individuals (n=954) was 68.8 years. Post-vaccination seroprotection rates (≥0.1 IU/mL for diphtheria/tetanus and ≥8 1/dilution for polio) for Group 1 were non-inferior to Group 2 for diphtheria (85.4% vs. 87.5%), tetanus (both 100%), polio type 1 (99.8% vs. 100%), polio type 2 (both 100%) and polio type 3 (99.3% vs. 99.8%). Similarly, percentages of individuals with pertussis antibodies ≥5 EU/mL for Group 1 were non-inferior to Group 2: pertussis toxin (94.3% vs. 98.1%), filamentous haemagglutinin (99.8% vs. 100%), pertactin (97.3% vs. 96.0%), fimbriae 2 and 3 (91.7% vs. 89.5%). Post-vaccination geometric mean titres of anti-influenza haemagglutinin antibodies for Group 1 were non-inferior to Group 2. Adverse events following administration of Tdap-IPV were similar in both study groups, with no vaccine-related serious adverse events.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>Tdap-IPV and inactivated influenza vaccine can be administered concomitantly in the elderly without impairing tolerability or the immune response to either vaccine.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23313654</PMID><DateCompleted><Year>2013</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>11</Issue><PubDate><Year>2013</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged ≥60 years: an open-label, randomised trial.</ArticleTitle><Pagination><MedlinePgn>1496-502</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2012.12.081</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(13)00010-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Annual influenza vaccination provides an opportunity to administer a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV) to the elderly. This study evaluated immune responses to and safety of the two vaccines administered concomitantly or sequentially to elderly individuals in France and Germany.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Individuals aged ≥60 years who had received a diphtheria/tetanus booster within 5-15 years were randomised (1:1) to receive either Tdap-IPV and an inactivated influenza vaccine concomitantly (Group 1) or inactivated influenza vaccine then Tdap-IPV 28-35 days later (Group 2). Antibody titres were measured before and 28-35 days after each vaccination.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean age of randomised individuals (n=954) was 68.8 years. Post-vaccination seroprotection rates (≥0.1 IU/mL for diphtheria/tetanus and ≥8 1/dilution for polio) for Group 1 were non-inferior to Group 2 for diphtheria (85.4% vs. 87.5%), tetanus (both 100%), polio type 1 (99.8% vs. 100%), polio type 2 (both 100%) and polio type 3 (99.3% vs. 99.8%). Similarly, percentages of individuals with pertussis antibodies ≥5 EU/mL for Group 1 were non-inferior to Group 2: pertussis toxin (94.3% vs. 98.1%), filamentous haemagglutinin (99.8% vs. 100%), pertactin (97.3% vs. 96.0%), fimbriae 2 and 3 (91.7% vs. 89.5%). Post-vaccination geometric mean titres of anti-influenza haemagglutinin antibodies for Group 1 were non-inferior to Group 2. Adverse events following administration of Tdap-IPV were similar in both study groups, with no vaccine-related serious adverse events.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Tdap-IPV and inactivated influenza vaccine can be administered concomitantly in the elderly without impairing tolerability or the immune response to either vaccine.</AbstractText><CopyrightInformation>Copyright © 2013 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zimmermann</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Internistische Gemeinschaftspraxis, Sülmerstraße 32, D74072, Heilbronn, Germany. Dr.UlrichZimmermann@web.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gavazzi</LastName><ForeName>Gaëtan</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Richard</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Eymin</LastName><ForeName>Cécile</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Soubeyrand</LastName><ForeName>Benoît</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Baudin</LastName><ForeName>Martine</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000907">Antibodies, Bacterial</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C051021">DTPP vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015721">Diphtheria-Tetanus-Pertussis Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017778">Vaccines, Combined</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C478242">vaxigrip</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000907" MajorTopicYN="N">Antibodies, Bacterial</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015721" MajorTopicYN="N">Diphtheria-Tetanus-Pertussis Vaccine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="N">Immunization, Secondary</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017778" MajorTopicYN="N">Vaccines, Combined</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23313654</ArticleId><ArticleId IdType="pii">S0264-410X(13)00010-8</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2012.12.081</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li></country></list><tree><noCountry><name sortKey="Baudin, Martine" sort="Baudin, Martine" uniqKey="Baudin M" first="Martine" last="Baudin">Martine Baudin</name><name sortKey="Eymin, Cecile" sort="Eymin, Cecile" uniqKey="Eymin C" first="Cécile" last="Eymin">Cécile Eymin</name><name sortKey="Gavazzi, Gaetan" sort="Gavazzi, Gaetan" uniqKey="Gavazzi G" first="Gaëtan" last="Gavazzi">Gaëtan Gavazzi</name><name sortKey="Richard, Patrick" sort="Richard, Patrick" uniqKey="Richard P" first="Patrick" last="Richard">Patrick Richard</name><name sortKey="Soubeyrand, Benoit" sort="Soubeyrand, Benoit" uniqKey="Soubeyrand B" first="Benoît" last="Soubeyrand">Benoît Soubeyrand</name></noCountry><country name="Allemagne"><noRegion><name sortKey="Zimmermann, Ulrich" sort="Zimmermann, Ulrich" uniqKey="Zimmermann U" first="Ulrich" last="Zimmermann">Ulrich Zimmermann</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeAllemagneV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000210 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000210 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeAllemagneV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:23313654
|texte= Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged ≥60 years: an open-label, randomised trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23313654" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeAllemagneV4
| This area was generated with Dilib version V0.6.35. |  |